A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the full dose of eribulin mesylate can be safely
given with the full dose of cetuximab. The activity of the combination of eribulin mesylate
and cetuximab on recurrent head and neck cancer and colon cancer will also be assessed.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
howard safran
Collaborators:
Fatima Memorial Hospital Montefiore Medical Center Rhode Island Hospital The Miriam Hospital